IJTLD open最新文献_第5页

Lung life HRQoL measure: psychometric properties and initial data in presumptive TB. 肺部生活 HRQoL 测量：推定肺结核患者的心理测量特性和初始数据。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0580

M G Anthony, G Hoddinott, C Purdy, V Luke, M Van Niekerk, A C Hesseling, M M van der Zalm

{"title":"Lung life HRQoL measure: psychometric properties and initial data in presumptive TB.","authors":"M G Anthony, G Hoddinott, C Purdy, V Luke, M Van Niekerk, A C Hesseling, M M van der Zalm","doi":"10.5588/ijtldopen.24.0580","DOIUrl":"10.5588/ijtldopen.24.0580","url":null,"abstract":"Introduction: Health-related quality of life (HRQoL) data in young children with respiratory illnesses, including TB, are limited in low- and middle-income countries (LMICs). This study assessed the psychometric properties of the LuLi-Q measures in South African children with presumptive TB, focusing on children aged 0-5 years.Methods: In a cross-sectional study within the UMOYA TB diagnostic study, HRQoL data were collected using the LuLi-Q-Tots (0-2 years) and LuLi-Q-Pres (3-5 years) measures. Analyses included descriptive statistics, item-total correlations, and Cronbach's alpha for reliability.Results: Among 160 children aged 0-5 years (50 aged 0-2 years, 110 aged 3-5 years), the LuLi-Q-Tots had minimal floor and ceiling effects (6.5%), effectively capturing HRQoL. The LuLi-Q-Pres showed substantial floor and ceiling effects (61%), but removing 29 items improved reliability (Cronbach's alpha: 0.96-0.97). Caregivers reported daily medication use (54%) and anxiety (72%) in the 0-2 group, while separation anxiety (65%) and jealousy (92%) were common in the 3-5 group.Conclusion: This study establishes a foundation for reliable HRQoL measures for young children with presumptive TB, guiding future research and patient-centred care in LMICs.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 3","pages":"166-172"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anthropometric growth trajectories of children presenting with presumptive pulmonary TB. 假定肺结核患儿的人体测量生长轨迹。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0489

M V de Geus, M van Niekerk, C McKenzie, I Dewandel, J Zenhausern, E Wijstma, R Dunbar, H Rabie, A C Hesseling, V W Jongen, M M van der Zalm

{"title":"Anthropometric growth trajectories of children presenting with presumptive pulmonary TB.","authors":"M V de Geus, M van Niekerk, C McKenzie, I Dewandel, J Zenhausern, E Wijstma, R Dunbar, H Rabie, A C Hesseling, V W Jongen, M M van der Zalm","doi":"10.5588/ijtldopen.24.0489","DOIUrl":"10.5588/ijtldopen.24.0489","url":null,"abstract":"Background: This study assessed growth trajectories in children presenting with presumptive pulmonary TB (PTB).Methods: This sub-study of the Umoya TB diagnostic study was conducted in South Africa from November 2017 until November 2021. Children (0-13 years) with presumptive PTB were recruited from and followed up for 12 months. Anthropometric measurements of children with TB, symptomatic controls (TB excluded), and healthy controls were taken at baseline and follow-up (2, 8, 16, 24 and 52 weeks). Changes in weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ) and body mass index for age (BAZ) over time were assessed using multivariable mixed-effect linear regression adjusted for confounders.Results: Of the 372 children included in the analyses (median age: 2 years, IQR 1-4), 153 children had TB, 168 were symptomatic and 51 were healthy controls. Median WAZ was similar between groups; however, more children with TB were underweight than symptomatic and healthy controls. WAZ increased over time for children with TB. Median HAZ of children with TB (-1.34, IQR -2.17 to -0.21) was lower compared to symptomatic (-1.06, IQR -1.90 to -0.10) and healthy controls (-0.74, IQR -1.26 to -0.03; P = 0.0037). There was no significant change over time for HAZ.Conclusion: To improve the long-term outcomes of TB and other illnesses, the overall nutrition of children needs to be improved.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 3","pages":"137-144"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Western Pacific Regional Framework to End TB: overview and critical reflection. 西太平洋区域终止结核病框架：概述和批判性反思。

IJTLD open Pub Date : 2025-02-01 DOI: 10.5588/ijtldopen.24.0608

K H Oh, F Morishita, K Rahevar, R-P Yadav, H T G Tran, G B Marks, M C Raviglione, B J Marais

{"title":"The Western Pacific Regional Framework to End TB: overview and critical reflection.","authors":"K H Oh, F Morishita, K Rahevar, R-P Yadav, H T G Tran, G B Marks, M C Raviglione, B J Marais","doi":"10.5588/ijtldopen.24.0608","DOIUrl":"10.5588/ijtldopen.24.0608","url":null,"abstract":"Despite notable progress, TB remains a critical public health challenge in the Western Pacific Region. To address this, the WHO developed the Western Pacific Regional Framework to End TB, which aligns with global health targets, such as the End TB Strategy and the Sustainable Development Goals. Here, we critically review the Framework, highlighting its strengths and ongoing challenges, with suggestions as to how it might adapt. Although the Framework offers a comprehensive strategy for reducing the TB burden, its success depends on effective implementation across diverse socio-economic contexts. Key obstacles include undiagnosed infectious TB cases, limited healthcare infrastructure, persistent inequities in access to TB services, and drug-resistant TB. The COVID-19 pandemic exacerbated these challenges, disrupting TB services and delaying progress towards 2030 targets. The Framework's reliance on multisectoral partnerships and innovative technologies presents opportunities but requires substantial political commitment, sustained funding and system-wide health reforms. Additionally, gaps remain in addressing social determinants of TB. Ensuring equity, maintaining political will, and fostering international collaboration are essential to overcoming these barriers. Continuous evaluation and adaptation will be crucial in ensuring the Framework's effectiveness in eliminating TB in the Region by 2030.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 2","pages":"64-72"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe. 在欧洲使用假定的肝保护剂作为抗结核治疗的辅助手段。

IJTLD open Pub Date : 2025-02-01 DOI: 10.5588/ijtldopen.24.0498

O Kirakosyan, M Reimann, A B Andersen, A Bjarnason, Á Bakos, A M Dyrhol-Riise, A M McLaughlin, C Nita, D Pieridou, D Chesov, E V Davidavičienė, G Günther, H Atshemyan, I Muylle, I Solovic, J Bruchfeld, K Manika, L Kuksa, L R Codecasa, M Stosic, M Skowroński, M J Makek, M Fréchet Jachym, M Knappik, M Santin, N Yatskevich, O Konstantynovska, O Akkerman, P Svetina, P Viiklepp, R Duarte, S Zeynel, T Togonidze, T Vasankari, V Parris, Ş Özkara, C Lange, T T Brehm

{"title":"Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe.","authors":"O Kirakosyan, M Reimann, A B Andersen, A Bjarnason, Á Bakos, A M Dyrhol-Riise, A M McLaughlin, C Nita, D Pieridou, D Chesov, E V Davidavičienė, G Günther, H Atshemyan, I Muylle, I Solovic, J Bruchfeld, K Manika, L Kuksa, L R Codecasa, M Stosic, M Skowroński, M J Makek, M Fréchet Jachym, M Knappik, M Santin, N Yatskevich, O Konstantynovska, O Akkerman, P Svetina, P Viiklepp, R Duarte, S Zeynel, T Togonidze, T Vasankari, V Parris, Ş Özkara, C Lange, T T Brehm","doi":"10.5588/ijtldopen.24.0498","DOIUrl":"10.5588/ijtldopen.24.0498","url":null,"abstract":"Background: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region.Methods: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group (TBnet) representatives in countries in the WHO European Region.Results: We received valid responses from 37 of 53 countries (69.8%), with 16 (43.2%) reporting regular use of putative hepatoprotective agents during anti-TB treatment. Half of these countries (n = 8) are part of the former Soviet Union. In five countries, these agents are recommended by national guidelines. The most commonly used hepatoprotective agents were silibin/silymarin (n = 9, 56.3%), ursodeoxycholic acid (n = 5, 31.3%), and soy phospholipids (n = 4, 25.0%). Treatment duration varied, with 56.3% (n = 9) using them for less than 1 month, 18.8% (n = 3) for 1-3 months, and 18.8% (n = 3) for 4-6 months.Conclusions: Putative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 2","pages":"101-106"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introducing a new series in IJTLD OPEN 'Ending the TB epidemic'. 在IJTLD OPEN中引入“终止结核病流行”新系列。

IJTLD open Pub Date : 2025-02-01 DOI: 10.5588/ijtldopen.24.0644

H D Blackbourn, G B Migliori

引用次数: 0

Ending the TB epidemic - what can we learn from the HIV epidemic? 终止结核病流行——我们能从艾滋病毒流行中学到什么？

IJTLD open Pub Date : 2025-02-01 DOI: 10.5588/ijtldopen.24.0618

A D Harries

引用次数: 0

Rapidly progressive silicosis previously diagnosed as pulmonary TB in mineworkers. 以前诊断为肺结核的矿工迅速进展性矽肺病。

IJTLD open Pub Date : 2025-02-01 DOI: 10.5588/ijtldopen.24.0564

J Pyana Kitenge, Q Said-Hartley, A Dubbeldam, I Kabeya Mulaji, P Kyansa Mangi, P Musa Obadia, M Jeebhay, S Ronsmans, B Nemery

引用次数: 0

Assessing the accuracy of the updated Fujifilm SILVAMP TB LAM II assay between lot numbers. 评估更新后的富士SILVAMP TB LAM II测定在批号之间的准确性。

IJTLD open Pub Date : 2025-02-01 DOI: 10.5588/ijtldopen.24.0449

K Chikamatsu, Y Shimomura, A Osugi, S Mitarai

{"title":"Assessing the accuracy of the updated Fujifilm SILVAMP TB LAM II assay between lot numbers.","authors":"K Chikamatsu, Y Shimomura, A Osugi, S Mitarai","doi":"10.5588/ijtldopen.24.0449","DOIUrl":"10.5588/ijtldopen.24.0449","url":null,"abstract":"Background: The Fujifilm SILVAMP TB LAM (FujiLAM) assay, a point-of-care test detecting urine-based lipoarabinomannans, has demonstrated notable diagnostic accuracy for TB. However, FujiLAM exhibits lot-to-lot variability, limiting its clinical use. A new version of the product, Fujifilm SILVAMP TB LAM II (FujiLAM II), was developed to address this issue. This study evaluated the lot-to-lot variability and diagnostic accuracy of the FujiLAM II.Methods: We assessed three lots of FujiLAM II using 158 biobanked, frozen urine specimens from people living with HIV (PLHIV): 72 TB-positive and 86 TB-negative, according to the microbiological reference standard.Results: Independent proportions of the results among the three FujiLAM II lots did not differ (Cochrane Q test: P > 0.37). Overall, sensitivities of the three FujiLAM II lots were 78.3%, 79.7% and 79.7%, and specificities were 92.9%, 93.0% and 93.0%, respectively. In patients with CD4 cell counts <200 cells/µL, sensitivities of the three FujiLAM II lots were 97.8%, 100% and 100%, and specificities were 91.7%, 91.8% and 91.8%, respectively.Conclusion: The FujiLAM II demonstrated no lot-to-lot variability and exhibited high sensitivity and specificity for TB diagnosis in patients with CD4 cell counts <200 cells/µL. The FujiLAM II enhanced reproducibility as a TB diagnostic tool in PLHIV.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 2","pages":"96-100"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Closing the gaps in childhood TB detection. 缩小儿童结核病检测方面的差距。

IJTLD open Pub Date : 2025-02-01 DOI: 10.5588/ijtldopen.24.0494

J Creswell, C Colvin

引用次数: 0

Comparative efficacy of tetracyclines against isolates of Mycobacterium avium complex. 四环素类药物对禽分枝杆菌复合体分离株的比较疗效。

IJTLD open Pub Date : 2025-02-01 DOI: 10.5588/ijtldopen.24.0551

S Singh, G D Boorgula, A Shrivastava, T Gumbo, S Srivastava

引用次数: 0